



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

8<sup>th</sup> April, 2025

Corporate Relationship Department  
M/s. BSE Limited  
Dalal Street, Fort  
Mumbai 400001

The Manager - Listing  
M/s. National Stock Exchange of India Ltd  
"Exchange Plaza", Bandra – Kurla Complex  
Bandra (E), Mumbai 400051

**Scrip Code: 524816**

**Scrip Code: NATCOPHARM**

Dear Sir/Madam,

**Sub:-** Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, we would like to inform you that in accordance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Legal Update regarding RISDIPLAM launch in India.

This is for your information and records.

Thanking you,

Yours faithfully,  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer

Encl: As above

**NATCO Pharma Ltd**

Natco House  
Road No.2, Banjara Hills  
Hyderabad-500 034, India

**Legal Update regarding Risdiplam**

Hyderabad, India, April 08<sup>th</sup>, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today updates on the legal proceedings on Risdiplam launch in India

The Company has received numerous enquiries from investors and patients about the launch, availability and pricing of generic version of Risdiplam in the Indian market. The Company wishes to clarify that the Ld. Single Judge of Delhi High Court had through order dated 24.03.2025 denied Roche's plea for an injunction against the Company for the drug. However, Roche has appealed the decision before the Appellate Bench of the Delhi High Court who has currently directed to maintain the status quo. Due to pendency of the proceedings before the court, the Company does not wish to comment on the status of the proceedings. However, it has been the stand of the Company that it intends to launch the drug only after and subject to successful clarity from the Appellate Bench of the Delhi High Court which is expected shortly.

Subject to the foregoing, the Company has decided to price the product at INR 15,900 MRP consistent with the Company's stand before the court. The Company also intends to offer discount to certain deserving patients through its patient access programme.

**About NATCO Pharma Limited**

NATCO Pharma Limited, (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company's manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at [www.natcopharma.com](http://www.natcopharma.com).

**For further information or queries please contact:**

Rajeev Menon – Manager, Investor Relations  
Email: [r.menon@natcopharma.co.in](mailto:r.menon@natcopharma.co.in)

Rajesh Chebiyam – EVP, Crop Health Sciences  
Email: [investors@natcopharma.co.in](mailto:investors@natcopharma.co.in)

Tel: 040-23547532 / Ext – 323

**Follow us on:**

X (formerly Twitter): [https://twitter.com/pharma\\_natco](https://twitter.com/pharma_natco)

LinkedIn: <https://www.linkedin.com/company/natcopharma>